Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Approach
    • Background
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • PHASE 3 (HEAL-AMI)
    • Phase 2B CHF
  • News Center
Learn how we approach
Regenerative Cardiac
Medicine of Tomorrow

Our Aim

Recardio is developing novel therapies that modulate and utilize the body’s own repair mechanisms in cardiovascular, oncology, and infectious diseases. Our lead candidate Dutogliptin is intended to enable cardiac regeneration in patients with Acute Myocardial Infarction (AMI) and Advanced Heart Failure (HF).

Read more

Company Profile

Recardio is a clinical stage life sciences company headquartered in San Francisco, California.

Our multinational management team and our scientific and clinical advisors are based in the US and in Europe.

Read more

News / Events

Recardio at J.P. Morgan Conference 2023

January 9, 2023

Recardio appoints Steering Committee for global Phase 3

November 1, 2022

Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design

June 1, 2022

Read More

Clinical Studies

Recardio’s global and multicenter Phase 2B study was completed and evaluated the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.

Read More

Careers

Being located in the US and Europe, we are committed to develop the regenerative therapies of the future. To support our clinical development, we are continuously looking to expand our team.

Read More

  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2023 · All Rights Reserved

Copyright © 2023 · Recardio on Genesis Framework · WordPress · Log in